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Ning Su1,2, Liang Peng1,2, Bingqing Xia1,2, Yingying Zhao1,2, Angao Xu3, Jing Wang1,2, Xinying Wang1,2*
and Bo Jiang1,2*Correction
To further confirm that the inactivation of Lyn inhibited
CD24-induced ERK1/2 activation, we submitted the results
of another CD24siRNA (CD24siRNA-2) as the Additional
file 1: Figure S2. After publication of the article [1] the
authors noted that the wrong figure for Additional file 1:
Figure S2 was submitted by mistake. The correct image
was conducted in SW480CD24 using CD24siRNA-2
(new Additional file 1: attached). The authors apologise for
any inconvenience caused.
Additional file
Additional file 1: Figure S1: Densitometry results of Figure 1A; Figure S2:
CD24siRNA-2 results; Figure S3: Means ± standard errors (SE) for three
independent experiments for Figure 4.
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